Brief: Eloxx Pharmaceuticals Announces First Patients Dosed In Phase 2B Exact Study Of Exaluren In Nonsense Mutation Alport Syndrome
11/09/2026 13:06
BRIEF-Eloxx Pharmaceuticals Announces First Patients Dosed In Phase 2B Exact Study Of Exaluren In Nonsense Mutation Alport Syndrome Sept 11 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O:
ELOXX PHARMACEUTICALS ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2B EXACT STUDY OF EXALUREN IN NONSENSE MUTATION ALPORT SYNDROME
ELOXX PHARMACEUTICALS - TOPLINE DATA FROM 16-WEEK STUDY EXPECTED MID-2027; FINAL READOUT BY END OF 2027
Source text: ID:nPnkcFhta
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))